DaVita Inc. (DVA)
NYSE: DVA · Real-Time Price · USD
129.19
+1.17 (0.91%)
Oct 24, 2025, 4:00 PM EDT - Market closed
DaVita Employees
DaVita had 76,000 employees as of December 31, 2024. The number of employees increased by 6,000 or 8.57% compared to the previous year.
Employees
76,000
Change (1Y)
6,000
Growth (1Y)
8.57%
Revenue / Employee
$173,175
Profits / Employee
$11,004
Market Cap
9.24B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 76,000 | 6,000 | 8.57% |
| Dec 31, 2023 | 70,000 | 0 | - |
| Dec 31, 2022 | 70,000 | 1,000 | 1.45% |
| Dec 31, 2021 | 69,000 | 2,000 | 2.99% |
| Dec 31, 2020 | 67,000 | 2,000 | 3.08% |
| Dec 31, 2019 | 65,000 | -12,700 | -16.34% |
| Dec 31, 2018 | 77,700 | 3,200 | 4.30% |
| Dec 31, 2017 | 74,500 | 4,200 | 5.97% |
| Dec 31, 2016 | 70,300 | 9,900 | 16.39% |
| Dec 31, 2015 | 60,400 | 2,500 | 4.32% |
| Dec 31, 2014 | 57,900 | 500 | 0.87% |
| Dec 31, 2013 | 57,400 | 4,000 | 7.49% |
| Dec 31, 2012 | 53,400 | 12,400 | 30.24% |
| Dec 31, 2011 | 41,000 | 4,500 | 12.33% |
| Dec 31, 2010 | 36,500 | 2,500 | 7.35% |
| Dec 31, 2009 | 34,000 | 1,500 | 4.62% |
| Dec 31, 2008 | 32,500 | 1,500 | 4.84% |
| Dec 31, 2007 | 31,000 | 2,100 | 7.27% |
| Dec 31, 2006 | 28,900 | 900 | 3.21% |
| Dec 31, 2005 | 28,000 | 12,700 | 83.01% |
| Dec 31, 2004 | 15,300 | 1,500 | 10.87% |
| Dec 31, 2003 | 13,800 | 800 | 6.15% |
| Dec 31, 2002 | 13,000 | 300 | 2.36% |
| Dec 31, 2001 | 12,700 | 500 | 4.10% |
| Dec 31, 2000 | 12,200 | -100 | -0.81% |
| Dec 31, 1999 | 12,300 | 0 | - |
| Dec 31, 1998 | 12,300 | 3,470 | 39.30% |
| Dec 31, 1997 | 8,830 | 5,705 | 182.56% |
| Dec 31, 1996 | 3,125 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
DVA News
- 6 days ago - DaVita Leads the Way in Evaluating Middle Molecule Clearance with Two New Initiatives - PRNewsWire
- 13 days ago - DaVita Inc. Schedules 3rd Quarter 2025 Investor Conference Call - PRNewsWire
- 2 months ago - DaVita Honors 25 Years of Clinical Advancement in Chronic Disease Care - PRNewsWire
- 2 months ago - Ransomware attack at dialysis firm DaVita affects 2.7 million people, US health dept website shows - Reuters
- 2 months ago - DaVita: Aggressive Buybacks Despite Rising Cost Of Debt - Seeking Alpha
- 2 months ago - DaVita Inc. (DVA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - DaVita beats quarterly profit on steady demand for dialysis services - Reuters
- 2 months ago - DaVita Inc. 2nd Quarter 2025 Results - PRNewsWire